Reunion Neuroscience Return on Equity

Reunion Neuroscience (REUN) currently reports a ROE of -225.6%. That is below the Healthcare sector average of 21.3%. Use the charts on this page to explore Reunion Neuroscience's ROE history and peer comparisons.

Reunion Neuroscience's ROE of -225.6% is lower than the Healthcare sector average of 21.3%. That is roughly 1159.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Reunion Neuroscience's current -225.6% should be judged against Healthcare norms (sector average: 21.3%) and against REUN's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -225.6%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.3%. From there, open related valuation or income-statement pages for Reunion Neuroscience, and consider following REUN for alerts when major investors trade the stock.

Reunion Neuroscience is classified in the Healthcare sector. On ROE, it currently shows -225.6% versus a sector average near 21.3%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing REUN with unrelated industries.